BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
What happened
Shares of South Korea’s HLB (028300) surged 29.95% to the daily upper limit at 39,700 won on Monday — the first trading day after the Chuseok holiday — after the U.S. FDA approved Lyfixtu (lirafugratinib), a treatment for FGFR2-altered bile duct cancer.
HLB’s U.S. subsidiary Elevar Therapeutics received the FDA approval on September 23 for second-line use in adults with locally advanced or metastatic bile duct cancer carrying FGFR2 fusions or rearrangements. HLB says this is the first time a Korean pharmaceutical company has filed a new drug application directly with the FDA for a global cancer drug and won clearance.
Why it matters
The approval is a landmark for Korea’s biotech sector: HLB went straight to the FDA instead of partnering with a Western pharma — a route few non-U.S. companies attempt. Elevar plans a Q4 2026 U.S. launch and has also filed with the European Medicines Agency (September 15).
The market reaction — hitting the price ceiling even in premarket on Nextrade — shows how much was riding on this decision. HLB had fallen roughly 39% for the year through September 23, after its liver cancer combo (rivoceranib + camrelizumab) received a third FDA complete response letter in July.
What to watch
Three things from here: (1) the U.S. launch price and payer uptake in Q4, (2) the EMA review outcome, and (3) whether this first-direct-FDA precedent opens the door for other Korean biotechs — and whether HLB’s liver cancer program can finally clear the FDA’s bar.
Related reading: Ligachem SOT106 Wins FDA Orphan Drug and Fast Track Status for Sarcoma; the Market Intelligence page also covered the September run-up in FDA approvals.
Sources:
https://en.sedaily.com/finance/2026/09/28/hlb-hits-daily-limit-after-first-fda-approval-of-korean
https://aistockwire.com/blog/hlb-028300-lyrfigtu-fda-approval-bile-duct-cancer-september-2026Does HLB’s direct-to-FDA route mark a turning point for Korean biotech going solo in the U.S., or was this a one-off win after a bruising year?
Auto-posted by the Bull Lounge news desk.
Not financial advice.Log in to vote
